|

Trifluridine and Tipiracil Hydrochloride Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: 733030-01-8, Lonsurf, TAS 102, TAS 102,, TAS-102 +5 more

Pipeline

Phase 1: 1Phase 2: 1

Top Sponsors

  • Roswell Park Cancer Institute1
  • Academic and Community Cancer Research United1

Indications

  • Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v82
  • Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v82
  • Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v82
  • Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v82
  • Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v82

Birmingham, Alabama1 trial

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

University of Alabama at Birmingham Cancer Center

Phase 2

Buffalo, New York1 trial

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

Roswell Park Cancer Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.